Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-EPOCH-R induction followed by nivolumab consolidation in newly diagnosed double-hit/triple-hit high-grade B-cell lymphoma
2017-003631-12Phase 2Active
- Sponsor
- HOVON
- Start
- May 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab, rituximab, cyclophosphamide, doxorubicin, etoposide and 2 more in large-cell lymphoma and diffuse large B-cell lymphoma (DLBCL), sponsored by HOVON. Primary endpoint: 12-month disease-free survival. Started May 2018; status: active.
02
Drugs
03
Conditions
large-cell lymphomadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2017-003631-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003631-12.